Sun Fights US Charges Over Delays
Indian Firm Pushes Back Against Charges Of Delaying Market Entry
You may also be interested in...
India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.
A Sun Pharma executive dismissed earlier this year has claimed retaliation by the company after she objected to the Indian firm’s alleged off-label marketing practices. Sun refutes the allegations and vows to vigorously defend itself, while experts suggest a settlement may be the way forward.
Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.